{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031467","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.987138+00:00","generated_at":"2026-06-04T19:06:18.973738+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026","bullets":["Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.","FDA discussions initiated for using tissue frataxin as surrogate endpoint for accelerated approval; BLA submission targeted for 2H 2025.","Open-label extension (OLE) study of 25 mg daily nomlabofusp dosed first patient in March 2024; interim data expected Q4 2024.","Raised $161.6M net proceeds from public offering in Feb 2024; cash position $86.8M at Dec 31, 2023 before offering.","Q4 2023 net loss $13.0M ($0.30/share) vs $9.4M ($0.21/share) in Q4 2022; R&D expenses $10.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031467","json":"https://secwatch.observer/filing/0000950170-24-031467.json","markdown":"https://secwatch.observer/filing/0000950170-24-031467.md","text":"https://secwatch.observer/filing/0000950170-24-031467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/0000950170-24-031467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/lrmr-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:06:18.973738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d0132770bf9c5e6fe62f55d5451ae6fd1995712","claim":"Larimar Therapeutics, Inc. reported the fourth quarter of 2023 and for the year ended December 31, 2023 results: net income $13.0 million, EPS $0.30 per share.","evidence_excerpt":"The Company reported a net loss for the fourth quarter of 2023 of $13.0 million, or $0.30 per share, compared to a net loss of $9.4 million, or $0.21 per share, for the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/0000950170-24-031467-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023 and for the year ended December 31, 2023"},{"label":"Net income","value":"$13.0 million"},{"label":"EPS","value":"$0.30 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}